Spyridon Gkalpakiotis

Associate professor

Charles University

Czech Republic

Research Interests

Explore related searches

Professors in Immunology

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Spyridon Gkalpakiotis is an Associate Professor at Charles University in the Czech Republic. His research primarily focuses on the management and implications of psoriasis and atopic dermatitis, as evidenced by his recent publications that examine real-world clinical, psychosocial, and economic burdens associated with these conditions. He is also involved in investigating treatment efficacy and safety regarding IL-17 inhibitors and other therapies in patients with dermatological disorders.

Articles (13)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Collaborators (2)

Razvigor Darlenski

BULGARIA

View details

Martin Tichý

Fakultní Nemocnice Olomouc

CZECH REPUBLIC

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Spyridon Gkalpakiotis

Research Interests

Explore related searches

Contact this professor

About

Articles (13)

Analysis of PEST Questionnaire Responses in Patients with Psoriasis in Daily Practice: Results from a Single-Center of Psoriasis in the Czech Republic

Real-World Clinical, Psychosocial, and Economic Burden of Atopic Dermatitis: Results From the ESSENTIAL AD Multicountry Study

Management of Moderate to Severe Plaque Psoriasis with Brodalumab in Daily Practice: Real-World Evidence from the LIBERO Study in the Czech Republic

Severe atopic dermatitis in a patient with Loeys‐Dietz syndrome treated with dupilumab

Correction to: Leg Ulcer Therapy by Local Injection of Autologous Growth Factors: Results of a Pilot Study

Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP )

Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors – brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry

Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry

Leg Ulcer Therapy by Local Injection of Autologous Growth Factors: Results of a Pilot Study

COVID-19 in 3 patients treated with immune checkpoint inhibitors for advanced melanoma

Adalimumab Biosimilar-Induced Severe Paradoxical Palmoplantar Pustulosis in a Patient with Psoriasis and Psoriatic Arthritis Successfully Treated with Ixekizumab

Alopecia barbae severity score: a novel scoring system to estimate the extent of beard loss and success of treatment

Risankizumab for the Treatment of Moderate-to-Severe Psoriasis: Real-Life Multicenter Experience from the Czech Republic

Collaborators (2)

Razvigor Darlenski

Martin Tichý

Make your next move.